Results 191 to 200 of about 8,772,279 (261)

Association of MHC class II β domain polymorphism in channel catfish (Ictalurus punctatus) with natural infection by Ligictaluridus floridanus. [PDF]

open access: yesParasitol Res
Roldán GMG   +5 more
europepmc   +1 more source

Dnmt3a Mutations Limit Normal and Autoreactive CD4+ T Follicular Helper Responses and Attenuate T Cell–Driven Joint Inflammation

open access: yesArthritis &Rheumatology, EarlyView.
Objective Somatic DNMT3A mutations are the most common drivers of clonal hematopoiesis in patients with rheumatoid arthritis (RA) and have been associated with seropositive disease and increased markers of inflammation. These mutations are predominantly hypomorphic or dominant‐negative, reducing DNMT3A function.
Yunbing Shen   +10 more
wiley   +1 more source

Case Report: A novel CIITA mutation causing MHC class II deficiency: first reported case in Morocco. [PDF]

open access: yesFront Immunol
Kattra AB   +9 more
europepmc   +1 more source

Type I Interferon Drives Dysfunction of a Distinct CD8+ HLA‐DRB1+ T Cell Subset in Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is characterized by type I interferon (IFN) signaling and adaptive immune dysregulation. We previously identified hypomethylation of HLA‐DRB1 and STAT1 in SLE CD8+ T cells, enabling aberrant IFN‐driven HLA‐DRB1 expression and expansion of a distinct CD8+ T cell subset. This study characterized CD8+ HLA‐DRB1+
Huizhong Long   +3 more
wiley   +1 more source

A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia. [PDF]

open access: yesBlood Cancer J
Golick L   +7 more
europepmc   +1 more source

Single‐Cell RNA Sequencing of Peripheral Blood Defines Two Immunologic Subtypes of Sjögren's Disease Distinguished by Anti‐SSA Antibodies and Aberrant B Cell Populations

open access: yesArthritis &Rheumatology, EarlyView.
Objective Sjögren's disease (SjD) is a heterogeneous autoimmune disorder characterized by substantial clinical and molecular diversity. This heterogeneity raises key questions regarding the existence of distinct pathogenic mechanisms underlying disease subtypes.
Geoffrey Urbanski   +15 more
wiley   +1 more source

Exploring MHC class II I-Ab blockade as a potential treatment for Sjögren's disease in the mouse model. [PDF]

open access: yesImmunohorizons
Voigt A   +7 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

H18 haemagglutinin binds MHC class II at a site distant from the canonical sialic-acid binding site

open access: yes
Wrobel A   +23 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy